POMDOCTOR Resolves Nasdaq Delisting Threat by Regaining Compliance
POM sits 33% above its 52-week low of $1.168 on light trading volume (0.1× avg).
Summary
POMDOCTOR regained Nasdaq compliance after its ADS price held above $1.00 for 10 consecutive days, closing the delisting matter. The company remains under financial pressure with a going concern warning.
Key Events · Legal and Risk Events · POM
-
Nasdaq Compliance Regained
On July 10, 2026, Nasdaq confirmed that POMDOCTOR's ADS closing bid price was at or above $1.00 for 10 consecutive business days (June 25 – July 9, 2026), satisfying the minimum bid price requirement under Rule 5450(a)(1). The delisting matter is now closed.
-
Delisting Risk Removed
The compliance resolution eliminates the immediate threat of delisting that had been pending since the January 29, 2026 deficiency notice. The stock will continue trading on Nasdaq under ticker POM.
-
Reverse Split Enabled Compliance
The primary mechanism that lifted the ADS price above $1.00 was the 1-for-18 reverse ADS split effective June 22, 2026, allowing the company to meet the bid price requirement.
-
Financial Distress Persists
Despite regaining listing compliance, POMDOCTOR still faces a going concern warning from its auditor and reported a significantly widened net loss and massive operating cash burn for fiscal 2025, as disclosed in May 2026.
Analysis · POM · Trade & Services
A critical overhang that threatened POMDOCTOR's exchange listing has been resolved. On July 10, 2026, the company received confirmation that its ADS price stayed above $1.00 for 10 consecutive business days, satisfying the minimum bid price rule. This removes the immediate delisting threat that had been hanging over the stock since January 2026, though the company still faces severe financial distress including a going concern warning and massive operating losses disclosed in May.
At the time of this filing, POM was trading at $1.55 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $11.4M. The 52-week trading range was $1.17 to $115.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.